CombiMatrix Corporation (NASDAQ:CBMX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On August 3, 2017, CombiMatrix Corporation (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2017. A copy of that release is furnished as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated August 3, 2017 of the Registrant (furnished herewith but not filed to Item 2.02).
The information in Item 2.02 of this Current Report on Form 8-K and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement or other document or filing to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COMBIMATRIX CORPORATION | |||
| Dated: | August 3, 2017 | By: | /s/ SCOTT R. BURELL |
| Scott R. Burell, Chief Financial Officer |
Exhibit Index
| Exhibit Number | Description |
| 99.1 | Press Release dated August 3, 2017 of the Registrant (furnished herewith but not filed CombiMatrix Corp ExhibitEX-99.1 2 ex99-1.htm CombiMatrix Corporation Reports Second Quarter 2017 Financial and Operating Results IRVINE,…To view the full exhibit click hereAbout CombiMatrix Corporation (NASDAQ:CBMX) CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders. |
